Icecure Medical Ltd Dossier
Qualitative Analysis
Business overview
IceCure Medical Ltd. (NASDAQ: ICCM) is a commercial-stage medical device company headquartered in Caesarea, Israel, specializing in the research, development, and commercialization of minimally invasive cryoablation systems. The company's proprietary liquid-nitrogen-based (LN2) technology, notably its flagship ProSense® system, destroys benign and cancerous tumors by freezing them in situ. This technology serves as a safe, effective, and convenient alternative to traditional surgical tumor removal, allowing for short, office-based procedures. IceCure's primary clinical focus areas include breast, kidney, lung, and bone cancers.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Enhancing market penetration efforts in the U.S. following FDA clearance for low-risk breast cancer at the end of 2025, including expanding commercial infrastructure and launching the post-marketing 'ChoICE' study.
Expected impact: Broaden clinical adoption, increase active commercial install base, and drive disposable probe and system revenues.
Pursuing regulatory approvals for ProSense® in additional global markets, including the Class III amendment application in Canada and supporting Terumo's upcoming submission in Japan.
Expected impact: Open up new geographic markets, expanding the addressable patient population globally.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Terumo acts as the exclusive distributor of ProSense® in Japan and is leading the regulatory submission process for breast cancer clearance with Japan's PMDA.
Terms: Includes milestone payments and product transfer pricing; previously recognized $100,000 from the agreement and other services in Japan.
Turing Medical is responsible for marketing, promoting, distributing, and maintaining regulatory approvals for IceCure's cryoablation systems in mainland China.
Terms: Turing is responsible for obtaining and maintaining regulatory approvals from China's NMPA.